Jian Zhang

Giuseppe M.C. Rosano

President Heart Failure Association Giuseppe M.C. Rosano, MD, PhD, is Director of the Cardiovascular translational laboratory at IRCCS San Raffaele Roma where he is also Professor of Pharmacology and Consultant Cardiologist. G.R. received his medical degree and his specialisation in cardiovascular medicine from “La Sapienza” University of Rome in Rome, Italy, and his PhD in Medical Sciences from the Imperial College of Science and Technology in London, United Kingdom. G.R. has served as member of the CVWP of the European Medicines Agency since July 2020, he has been board member of the Italian Space Agency and member of the pricing and reimbursement committee at the Italian Drug Agency. G.R. is fellow of the European Society of Cardiology, the Heart Failure Association, the American College of Cardiology, and the Italian Federation of Cardiology. He serves as Editorial Board Member for European Heart Journal, European Journal of Heart Failure, European Heart Journal—Cardiovascular Pharmacotherapy, ESC Heart Failure, Cardiovascular Diabetology, Nature Research Scientific Reports, Cardiovascular Reviews, Advances in Therapy, European Cardiology Review, and Climacteric. G.R. has authored or co-authored more than 600 peer-reviewed articles. He is the president of the Heart Failure Association of the ESC.

Curriculum Vitae

Giuseppe Massimo Claudio Rosano is a distinguished international authority in cardiovascular medicine, regulatory science, and pharmacology. He serves as a Professor of Cardiology and Consultant Cardiologist at St George’s University of London and St George’s Hospitals NHS Trust. Concurrently, he maintains prominent academic ties in Italy as a Professor of Pharmacology and serves as a vital medical director.

Throughout his prolific career, Professor Rosano has accumulated extraordinary expertise in regulatory and committee spheres, notably serving as the Past-President of the Heart Failure Association of the ESC, a long-standing member of the Cardiovascular Working Party at the European Medicines Agency (EMA), and a senior board member for the Italian Drug Agency (AIFA). With over 820 publications, a remarkable H-index of 131, and more than 85,000 citations, his professional focus centers on clinical trial assessment, molecular medicine pathways, and metabolic-endocrine cardiovascular conditions.